November 15, 2023

Dr. Lahar Mehta Speaks About New Trial to Evaluate ALS Drug for Progressive Supranuclear Palsy

25 minutes

This episode features an interview with Dr. Lahar Mehta, Head of Global Clinical Development at Amylyx Pharmaceuticals, who spoke to Xtalks about Amylyx’s clinical trial design of ORION, a Phase III Global Study of AMX0035 (Relyvrio) in Progressive Supranuclear Palsy (PSP).

The company presented details about the trial at the Neuro2023 PSP and CBD International Research Symposium that took place in London last month in October. The ORION study will evaluate the safety, efficacy, and tolerability of AMX0035 in PSP patients. The drug was approved by the FDA last year for the treatment of ALS.

PSP is a rare, progressive, adult-onset neurological disorder that affects body movements, walking and balance, eye movement, swallowing, and speech. There are currently no approved medicines to treat PSP.

Hear more about the details of the trial, which is set to begin in December this year.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Twitter: @Xtalks

Instagram: @Xtalks

Facebook: https://www.facebook.com/Xtalks.Webinars/

LinkedIn: https://www.linkedin.com/company/xtalks-webconferences

YouTube: https://www.youtube.com/c/XtalksWebinars/featured

...more